+82-2-740-8245 (Office)
+82-2-3668-7636 (Lab)
inhee@snu.ac.kr
1. A breakdown in
metabolic reprogramming causes microglia dysfunction in Alzheimer’s disease.
Cell Metabolism (2019) 30(3):493-507.
2. Transfer of a healthy
microbiota reduces amyloid and tau pathology in an Alzheimer’s disease animal
model. Gut (2019) 69(2):283-294.
3. Plasma tau/amyloid
beta1-42 ratio predicts brain tau deposition and neurodegeneration in
Alzheimer’s disease. Brain (2019) 142(3):771-786.
1.
Molecular pathogenesis of
Alzheimer’s disease
(1) Abeta-tau axis
(2) Tau propagation in
the brain
(3) Brain inflammation
including microglial function
(4) Gut-brain axis
(5) Crosstalk between
peripheral and CNS immune system
2.
Identification of plasma biomarkers
for early diagnosis of dementia
3.
Therapeutic approaches for
Alzheimer’s disease drug development
(1) Patient-derived brain
organoids and microglia
(2) Platform development
of drug screening
(3) Development of
preclinical animal models
TOP